Bill > SB1091

This bill establishes the Pharmaceutical Transparency Review Board, an independent body tasked with reviewing high-cost prescription drug products and developing recommendations to address affordability burdens faced by residents, government agencies, health plans, providers, employers, and other stakeholders. The bill requires manufacturers to report detailed information on the costs, pricing, and financial incentives related to certain prescription drugs, which the board will analyze and publish reports on. The bill also creates the Pharmaceutical Transparency Review Fund, which will be funded by assessments on manufacturers to support the board's activities.